Genentech's astegolimab cut COPD exacerbations in ALIENTO but missed significance in Phase 3 ARNASA—exposing a broken biomarker stratification logic...
Infex RESP-X shows safety, reduces exacerbations in bronchiectasis trial. Quarterly dosing monoclonal targets pseudomonas virulence.
TaiMed Biologics completes Phase 2b enrollment for TMB-365/380 HIV therapy, a dual antibody combination dosed every two months without...
Nuvalent neladalkib achieves oral presentation at 2026 ASCO for ALK-positive NSCLC, with NDA filed in April ahead of FDA...
Sapience's lucicebtide demonstrated 28.4-month median progression-free survival in newly diagnosed glioblastoma, significantly exceeding historical benchmarks i
Astegolimab cut COPD exacerbations in Phase 2b but missed in Phase 3—a 14.5% gap that exposes critical flaws in...
Tedopi Plus Pembrolizumab extends median PFS to 4.1 months in platinum-sensitive recurrent ovarian cancer, marking the first positive randomized...
BIIB122 fails to slow motor decline in early Parkinson's disease trial despite strong target engagement and biomarker effects.
Phesi's 2026 analysis found fewer than 1 in 3 trial protocols are linked to patient data—meaning AI tools are...
EMA's first 2026 quarterly report shows only 40.5% of EU trials recruiting within 200 days — far below the...
